#4 – How ECCMID 2019 went viral

07/10/19 • 31 min

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2).

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Previous Episode

#3 – Lessons Learned From the Front Line

In the final part of our three part series on penicillin allergies host Jason Pogue (@jpogue1) and our expert panelists Julie Ann Justo (@julie_justo), Bruce Jones (@Bruce_M_Jones), and Mary Staicu (@marylynnstaicu) discuss important clinical pearls and lessons learned from the front line that can be helpful for those interested in starting a penicillin allergy program. The panel then wraps up by discussing future directions for penicillin allergy management.

This podcast is powered by Pinecast.

Next Episode

#5 – Nerding Out at ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share their secret passions and nerdiest moments from ECCMID 2019, including multi-omics data for Pseudomonas aeruginosa, the effects of chemotherapy on antimicrobial resistance, phage therapy, and more!